Compare
UroGen Pharma Ltd. vs Zevra Therapeutics, Inc. vs Lifecore Biomedical, Inc. vs Cytokinetics Inc
| Latest fiscal year | UroGen Pharma Ltd. URGN | Zevra Therapeutics, Inc. ZVRA | Lifecore Biomedical, Inc. LFCR | Cytokinetics Inc CYTK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-05-25 | 2025-12-31 |
| Revenue | $109.79M | $106.47M | $128.87M | $88.04M |
| Revenue growth (YoY) | +21.4% | +350.9% | +0.5% | +376.6% |
| Gross margin | 88.7% | n/a | 31.3% | n/a |
| Operating margin | -113.7% | -59.1% | -13.4% | -695.4% |
| Net margin | -139.8% | 78.2% | -30.0% | -891.6% |
| Net income | -$153.49M | $83.23M | -$38.72M | -$784.96M |
| EPS (Diluted) | n/a | $1.35 | -$1.27 | -$6.54 |
| Operating cash flow | -$162.44M | -$1.60M | -$206.0K | -$510.01M |
| Free cash flow | -$162.73M | -$2.43M | -$13.62M | -$534.82M |
| Cash & equivalents | $110.75M | $62.41M | $8.27M | $122.52M |
| Total assets | $200.46M | $284.73M | $239.34M | $1.42B |
| Total liabilities | $305.93M | $130.07M | $191.91M | $2.08B |
| Shareholders' equity | -$105.47M | $154.66M | $1.34M | -$659.62M |
| Return on year-end equity | n/a | 53.8% | n/m | n/a |
| Shares outstanding | 48.35M | 56.85M | 37.03M | 122.94M |
Revenue, most recent five fiscal years
| Fiscal year | UroGen Pharma Ltd. | Zevra Therapeutics, Inc. | Lifecore Biomedical, Inc. | Cytokinetics Inc |
|---|---|---|---|---|
| Latest | $109.79M Ended 2025-12-31 | $106.47M Ended 2025-12-31 | $128.87M Ended 2025-05-25 | $88.04M Ended 2025-12-31 |
| 1 year earlier | $90.40M Ended 2024-12-31 | $23.61M Ended 2024-12-31 | $128.26M Ended 2024-05-26 | $18.47M Ended 2024-12-31 |
| 2 years earlier | $82.71M Ended 2023-12-31 | $27.46M Ended 2023-12-31 | $103.27M Ended 2023-05-28 | $7.53M Ended 2023-12-31 |
| 3 years earlier | $64.36M Ended 2022-12-31 | $10.16M Ended 2022-12-31 | $111.27M Ended 2022-05-29 | $94.59M Ended 2022-12-31 |
| 4 years earlier | $48.04M Ended 2021-12-31 | $28.65M Ended 2021-12-31 | $100.87M Ended 2021-05-30 | $70.43M Ended 2021-12-31 |